Novel Drug Safe, Effective in Relapsing MS: 2-Year Data : vi

The investigational evobrutinib, an Bruton's tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.

Related Keywords

New York , United States , Maryland , Stony Brook , National Harbor , Missouri , Texas , Patriciak Coyle , Jerrys Wolinsky , Hanne Cross , Consortium Of Multiple Sclerosis Centers , Department Of Neurology , Mcgovern Medical School , Trotter Multiple Sclerosis Center , Stony Brook University Medical Center , Texas Health Science Center , Medscape Medical , Multiple Sclerosis Centers , Medscape Medical News , New England Journal , Expanded Disability Status Scale , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Drug Development , Monoclonal Antibody , Etuximab , Ituximab , Biologic Therapy , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Disability , Cancer , Alignant Neoplasia , Arcinoma , Magnetic Resonance Imaging Mri , Magnetic Resonance I ,